Jinhe Biotechnology Co., Ltd.

Jinhe Biotechnology Co., Ltd. is a high-tech enterprise founded in 1990 and listed on the Shenzhen Stock Exchange in 2012. The company specializes in the research and development, production, sales, and service of animal health products, offering integrated solutions primarily in the veterinary sector. Jinhe is recognized as a leading manufacturer of veterinary chemical chlortetracycline premix and holds the position of the world's largest producer in this category. The company's operations are structured around two main business segments: veterinary chemicals and veterinary vaccines. In the veterinary chemicals segment, Jinhe focuses on chlortetracycline premix and a range of other veterinary chemical products, which are utilized in various global markets, including the United States, Europe, and Asia. The veterinary vaccines segment, established in 2015, has expanded through strategic acquisitions and now includes multiple production bases and research centers. Jinhe's vaccine portfolio covers swine, ruminant, and pet vaccines, with a strong emphasis on innovation and quality, evidenced by its advanced R&D capabilities and established product pipeline.

1. Advantages in Technology R&D Veterinary Chemicals Business For over 30 years, the company has been dedicated to the R&D and production of chlortetracycline products, accumulating a vast reservoir of technical data, mastering internationally advanced fermentation processes and practical production experience, and establishing technology development and production process standards that comply with international norms. The company's chlortetracycline products are manufactured with advanced processes and equipment and feature high automation. It possesses independently developed high-yield strains, which contribute to shorter production cycles, outstanding cost competitiveness and distinct technical advantages. On the basis of independent R&D, the company has actively carried out extensive technical cooperation with domestic research institutes and universities, and accelerated the industrial application and layout of synthetic biology, providing sustained and robust support for product R&D and technological innovation through technological upgrades. Veterinary Vaccines Business The company has established two R&D centers for animal vaccines (the U.S. R&D Center and Jinhe Uben Research Institute) and built four core technology platforms. Leveraging its overseas Pharmgate Biologics Inc. R&D Center, it has set up a R&D and innovation platform with a global perspective. Domestically, the company has a R&D hub centered on Jinhe Uben Research Institute, which conducts intensive collaborative research with renowned domestic scientific research institutions. The research scope covers the innovation and optimization of product process technology, full-process monitoring and quality control of vaccine production, and technical testing services for customers. It realizes modular collaboration from antigen construction to new veterinary drug registration, truly establishing the most systematic and fully functional research institution in China's animal vaccine industry. Through complementary R&D efforts at home and abroad, the company has formed a development pattern for fully exploring the global vaccine market. 2. Stable and Reliable Product Quality with High Industry Recognition and Reputation Veterinary Chemicals Business The production processes and technologies for the company's products such as chlortetracycline premix and chlortetracycline hydrochloride are mature, with stable and reliable product quality, earning the trust and praise of a wide range of customers. As early as 2002, the company's relevant products obtained the Veterinary Drug Good Manufacturing Practice Certification from the Ministry of Agriculture and Rural Affairs of China. Since 1994, it has successfully passed the U.S. Food and Drug Administration quality inspections eight consecutive times, and also passed quality audits conducted by multiple well-known overseas customers. The company's brand enjoys high visibility and reputation in the industry, and its trademark "Jinhe" has been recognized as a Well-known Trademark by the State Administration for Market Regulation. Veterinary Vaccines Business The company has always adhered to the core philosophy of "Purity", and on this basis, strictly abides by the "Three Principles of Uben Quality", truly ensuring that all products delivered to customers maintain uniformly stable quality standards. With safe, efficient, stable and high-quality vaccine products and solutions, it safeguards animal health and contributes to human well-being. Uben Vaccines owns four core process technology platforms—the Antigen Industrial Mass Production Platform, Antigen Purification Platform, Antigen Quantitative Detection Platform and Genetic Engineering Subunit Antigen Construction Platform—which effectively guarantee the unique product quality of "Purity". The company has carried out upgrading and transformation of multiple products, all of which have achieved breakthrough progress. 3. Diversified Product Portfolio Enhances Risk Resistance and Supports Sustainable Growth Veterinary Chemicals Business The company's original annual production capacity of chlortetracycline stood at 55,000 tons. With the commissioning of the newly built Phase VI Project, an additional annual capacity of 60,000 tons (equivalent to chlortetracycline premix with 15% content) has been added, realizing a substantial capacity expansion and fully meeting the future market growth demand for veterinary chemical products. After the Phase VI Project went into production, the company re-planned its old and new production bases based on market demand, designating them for the production of chlortetracycline, oxytetracycline and other veterinary chemical products. Veterinary Vaccines Business Currently, the company has 17 vaccine products on the market, forming a relatively diversified veterinary vaccine product portfolio, including swine vaccines (mainly PRRS vaccine, porcine circovirus vaccine, Swine Mycoplasma Hyopneumoniae Vaccine, Porcine Circovirus Type 2, Mycoplasma Hyopneumoniae Inactivated Vaccine, porcine parvovirus vaccine, inactivated swine erysipelas vaccine, live classical swine fever vaccine, live porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent vaccine, etc.), ruminant vaccines (brucellosis vaccine, inactivated lumpy skin disease vaccine for cattle [which has passed emergency evaluation]), pet vaccines (mainly inactivated rabies vaccine) as well as related diagnostic reagents supporting the vaccines. The company continues to focus on the pet medicine sector, with 15 products currently available for sale, including 8 health products (under its own brand), 6 functional foods and 1 rabies vaccine. The company has more than ten products under registration, including anthelmintics, therapeutic drugs and vaccines. The launch of ruminant vaccines and pet medicine products will further create new performance growth drivers for the company, optimize its revenue structure, play a significant role in offsetting the impact of the swine cycle, and greatly enhance the company's comprehensive strength in the animal health business sector. 4. Established a Global Sales Network The company has built a global sales network. Domestically, its marketing center has set up six major regions nationwide, with more than a dozen sub-regions under each major region, forming a nationwide sales network that can provide customers with high-quality and efficient product services and technical consulting. In the international market, the international marketing center and Pharmgate Biologics Inc. have established a sales network radiating key global markets through multiple channels such as setting up sales branches and appointing agents. It has also expanded its sales network from veterinary chlortetracycline to veterinary vaccines, giving full play to the synergistic effect. 5. Distinct Cost Advantages The company's production capacity for veterinary chemicals is mainly located in Inner Mongolia, and it leverages its geographical advantages to drive down product costs. Firstly, in terms of raw material costs, Inner Mongolia is a major corn-producing region in China, giving the company prominent advantages in procurement, transportation and storage. Secondly, in terms of energy, the prices of coal and electricity in Inner Mongolia have obvious advantages over other provinces. The company is adjacent to the Junggar Coal Mine—the largest open-pit coal mine in Asia—and the Datang Tuoketuo Power Plant—the world's largest thermal power plant, enabling it to purchase coal and electricity at relatively low costs. In addition, the Phase VI Project adopts more large-scale and intelligent equipment and facilities, which can effectively realize centralized mass production and intelligent management, further reducing the company's product costs.